Intracellular and plasma efavirenz concentrations in HIV-infected patients switching from successful protease inhibitor-based highly active antiretroviral therapy (HAART) to efavirenz-based HAART (SUSTIPHAR Study) | Zendy

Sarah Djabarouti | Zendy; Dominique Breilh | Zendy; Isabelle Pellegrin | Zendy; Michel Lavit | Zendy; Fabrice Camou | Zendy; O. Caubet | Zendy; Hervé Fleury | Zendy; M C Saux | Zendy; J.L. Pellegrin | Zendy

Open Access

Intracellular and plasma efavirenz concentrations in HIV-infected patients switching from successful protease inhibitor-based highly active antiretroviral therapy (HAART) to efavirenz-based HAART (SUSTIPHAR Study)

Author(s) -

Sarah Djabarouti,

Dominique Breilh,

Isabelle Pellegrin,

Michel Lavit,

Fabrice Camou,

O. Caubet,

Hervé Fleury,

M C Saux,

J.L. Pellegrin

Publication year - 2006

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkl348

Subject(s) - efavirenz , reverse transcriptase inhibitor , viral load , intracellular , pharmacokinetics , protease inhibitor (pharmacology) , sida , pharmacology , virology , gastroenterology , medicine , viral disease , biology , human immunodeficiency virus (hiv) , antiretroviral therapy , biochemistry

To assess intracellular and plasma efavirenz concentrations in HIV-infected patients who switched to efavirenz-based highly active antiretroviral therapy (HAART) from successful protease inhibitor-based HAART.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research